3m Company (NYSE: MMM), the global conglomerate, announced in early May it purchased Acelity Inc. for $6.7 billion, or roughly 11.4x EBITDA. The target is a medical device consortium comprised of Apax Partners, affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, is selling Acelity. Acelity develops advanced wound care products and specialty surgical applications marketed under the KCI brand name. The company reported a revenue of $1.5 billion in 2018.
This acquisition bolsters 3M’s Medical Solutions business and supports its growth strategy to offer comprehensive advanced and surgical wound care solutions. The transaction is expected to close in the second half of 2019. Advanced Wound Care seems to be a growing demand in the market across sectors.
On the very same day, Misonix, Inc. announced it was buying Solsys Medical LLC, a pharmaceutical company, for $117 million. Solsys Medical (fka Soluble Systems, LLC) markets an advanced wound care product under the brand name TheraSkin, a cellular and tissue-based product for regenerative wound healing. Upon closing, Misonix will own 64% of the company and Solsys unitholders will own 36%. The combined company is expected to generate roughly $80 million in sales in 2020.
In August 2018, Avista Healthcare Public Acquisition Corp. bought Organogenesis Inc., a medical device firm, for an undisclosed price. Organogenesis is a leading regenerative medicine company offering a portfolio of bioactive and cellular biomaterials products in advanced wound care and surgical biologics.
